Literature DB >> 20066428

Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2.

Anna Vihola1, Linda L Bachinski, Mario Sirito, Shodimu-Emmanuel Olufemi, Shohrae Hajibashi, Keith A Baggerly, Olayinka Raheem, Hannu Haapasalo, Tiina Suominen, Jeanette Holmlund-Hampf, Anders Paetau, Rosanna Cardani, Giovanni Meola, Hannu Kalimo, Lars Edström, Ralf Krahe, Bjarne Udd.   

Abstract

Aberrant transcription and mRNA processing of multiple genes due to RNA-mediated toxic gain-of-function has been suggested to cause the complex phenotype in myotonic dystrophies type 1 and 2 (DM1 and DM2). However, the molecular basis of muscle weakness and wasting and the different pattern of muscle involvement in DM1 and DM2 are not well understood. We have analyzed the mRNA expression of genes encoding muscle-specific proteins and transcription factors by microarray profiling and studied selected genes for abnormal splicing. A subset of the abnormally regulated genes was further analyzed at the protein level. TNNT3 and LDB3 showed abnormal splicing with significant differences in proportions between DM2 and DM1. The differential abnormal splicing patterns for TNNT3 and LDB3 appeared more pronounced in DM2 relative to DM1 and are among the first molecular differences reported between the two diseases. In addition to these specific differences, the majority of the analyzed genes showed an overall increased expression at the mRNA level. In particular, there was a more global abnormality of all different myosin isoforms in both DM1 and DM2 with increased transcript levels and a differential pattern of protein expression. Atrophic fibers in DM2 patients expressed only the fast myosin isoform, while in DM1 patients they co-expressed fast and slow isoforms. However, there was no increase of total myosin protein levels, suggesting that aberrant protein translation and/or turnover may also be involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066428      PMCID: PMC4199327          DOI: 10.1007/s00401-010-0637-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  67 in total

1.  Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q.

Authors:  C Schneider; A Ziegler; K Ricker; T Grimm; W Kress; C D Reimers; H Meinck; K Reiners; K V Toyka
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Expression of myogenic regulatory factors (MRFs) in human neuromuscular disorders.

Authors:  M Olivé; J A Martinez-Matos; P Pirretas; M Povedano; C Navarro; I Ferrer
Journal:  Neuropathol Appl Neurobiol       Date:  1997-12       Impact factor: 8.090

3.  Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy.

Authors:  A V Philips; L T Timchenko; T A Cooper
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

4.  Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?

Authors:  B Udd; R Krahe; C Wallgren-Pettersson; B Falck; H Kalimo
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

5.  Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene.

Authors:  H Haravuori; A Vihola; V Straub; M Auranen; I Richard; S Marchand; T Voit; S Labeit; H Somer; L Peltonen; J S Beckmann; B Udd
Journal:  Neurology       Date:  2001-04-10       Impact factor: 9.910

6.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

7.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

8.  NCAM, vimentin and neonatal myosin heavy chain expression in human muscle diseases.

Authors:  A Winter; A Bornemann
Journal:  Neuropathol Appl Neurobiol       Date:  1999-10       Impact factor: 8.090

9.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.

Authors:  C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum
Journal:  Science       Date:  2001-08-03       Impact factor: 47.728

10.  RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.

Authors:  N A Timchenko; Z J Cai; A L Welm; S Reddy; T Ashizawa; L T Timchenko
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

View more
  24 in total

1.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

Authors:  Olayinka Raheem; Shodimu-Emmanuel Olufemi; Linda L Bachinski; Anna Vihola; Mario Sirito; Jeanette Holmlund-Hampf; Hannu Haapasalo; Yi-Ping Li; Bjarne Udd; Ralf Krahe
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 2.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

Authors:  Linda L Bachinski; Keith A Baggerly; Valerie L Neubauer; Tamara J Nixon; Olayinka Raheem; Mario Sirito; Anna K Unruh; Jiexin Zhang; Lalitha Nagarajan; Lubov T Timchenko; Guillaume Bassez; Bruno Eymard; Josep Gamez; Tetsuo Ashizawa; Jerry R Mendell; Bjarne Udd; Ralf Krahe
Journal:  Neuromuscul Disord       Date:  2013-11-15       Impact factor: 4.296

4.  Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions.

Authors:  Mark Screen; Per Harald Jonson; Olayinka Raheem; Johanna Palmio; Reijo Laaksonen; Terho Lehtimäki; Mario Sirito; Ralf Krahe; Peter Hackman; Bjarne Udd
Journal:  Am J Pathol       Date:  2014-06-05       Impact factor: 4.307

5.  Prevalence and clinical correlates of sleep disordered breathing in myotonic dystrophy types 1 and 2.

Authors:  Maria Laura Ester Bianchi; Anna Losurdo; Chiara Di Blasi; Massimo Santoro; Marcella Masciullo; Giulia Conte; Venanzio Valenza; Antonello Damiani; Giacomo Della Marca; Gabriella Silvestri
Journal:  Sleep Breath       Date:  2013-12-06       Impact factor: 2.816

Review 6.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

7.  Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders.

Authors:  Linda L Bachinski; Mario Sirito; Maria Böhme; Keith A Baggerly; Bjarne Udd; Ralf Krahe
Journal:  Muscle Nerve       Date:  2010-12       Impact factor: 3.217

8.  Altered expression and splicing of Ca(2+) metabolism genes in myotonic dystrophies DM1 and DM2.

Authors:  A Vihola; M Sirito; L L Bachinski; O Raheem; M Screen; T Suominen; R Krahe; B Udd
Journal:  Neuropathol Appl Neurobiol       Date:  2013-06       Impact factor: 8.090

9.  Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.

Authors:  Massimo Santoro; Marcella Masciullo; Davide Bonvissuto; Maria Laura Ester Bianchi; Fabrizio Michetti; Gabriella Silvestri
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

10.  Deregulated microRNAs in myotonic dystrophy type 2.

Authors:  Simona Greco; Alessandra Perfetti; Pasquale Fasanaro; Rosanna Cardani; Maurizio C Capogrossi; Giovanni Meola; Fabio Martelli
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.